RenovoRx Q1 revenue $563K (+136% QoQ); net loss $3.5M; reaffirms FY revenue guidance $3-4M

RenovoRx, Inc.

2026-Q1 EPS reported -$0.09 revenue$563,000

Revenue $563,000, up 136% from Q4 2025; exceeds 50% of total FY2025 revenue.
Net loss $3.5M vs $2.4M a year ago; cash $12.4M with runway into H2 2027.
Active commercial cancer centers grew to 16 from 8 at year-end 2025; target 36 by year-end 2026.
Phase III TIGeR-PaC enrollment at 106 of 114 patients (93%); full enrollment expected by June 2026.
FY 2026 revenue guidance reaffirmed at $3-4 million.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RenovoRx, Inc. reported the first quarter ended March 31, 2026 results: revenue $563,000.

Period: the first quarter ended March 31, 2026
Revenue: $563,000
Result: reported results

Exact text from the filing

herein by reference. --- EX-99.1 (EX-99.1) --- EX-99.1 RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMPTM Therapy

View on SEC.gov

Browse all earnings releases →

RenovoRx, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-224080

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.